POST Online Media Lite Edition


Swiss Competition Commission investigates pharma suppliers

Christian Fernsby |
The Swiss Competition Commission (COMCO) has opened an investigation against several manufacturers and distributors of active pharmaceutical ingredients.

Article continues below


COMCO has conducted several dawn raids.

COMCO suspects that manufacturers and distributers of the active pharmaceutical ingredient Scopolamine Butylbromide have concluded unlawful price and market sharing agreements.

There are reasonable grounds to suspect that the undertakings have kept the prices of this pharmaceutical ingredient high and that they have allocated markets.

The investigation shall examine whether there are indeed unlawful restrictions of competition.

This pharmaceutical ingredient is used for the production of drugs against spasmodic stomach pains, renal colic and bladder spasms.

The manufacturers and distributors of Scopolamine Butylbromide resell this pharmaceutical ingredient to drug manufacturers.

What to read next

Pakistan's competition commission warns pharmaceutical sector of anti-competitive practices
Highlights: September 12 - September 16, 2016
Highlights: September 18 - September 21, 2017